Enveric Biosciences (ENVB) unveiled additional data indicating its lead development candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, a recognized therapeutic target for several central nervous system conditions including major depressive disorder and Parkinson’s disease. This adds to previously disclosed data showing EB-003 acts as a partial agonist of the 5-HT2A receptor. CEO Joseph Tucker stated the new data illustrates EB-003’s multifaceted mechanism of action and broadens its potential target indications. EB-003 is currently in preclinical development.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Psychedelic: Clearmind engages government, political affairs consulting firm
- Enveric Biosciences receives notice of allowance from USPTO
- Psychedelic: atai, Beckly Psytech to combine in all-share transaction
- Enveric Biosciences Holds 2025 Annual Stockholders Meeting
- Enveric gets U.S. patent for sleep, CNS therapeutics